Accessibility navigation

Antidiabetic effects of Bisamide Derivative of Dicarboxylic Acid in metabolic disorders

Pakhomova, V. P., Nebolsin, V. E., Pershina, O. V., Krupin, V. A., Sandrikina, L. A., Pan, E. S., Ermakova, N. N., Vaizova, O. E., Widera, D. ORCID:, Grimm, W.-D., Kravtsov, V. Y.’e., Afanasiev, S. A., Morozov, S. G., Kubatiev, A. A., Dygai, A. M. and Skurikhin, E. G. (2020) Antidiabetic effects of Bisamide Derivative of Dicarboxylic Acid in metabolic disorders. International Journal of Molecular Sciences, 21 (3). 991. ISSN 1422-0067

Text (Open Access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.

[img] Text - Accepted Version
· Restricted to Repository staff only


It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.3390/ijms21030991


In clinical practice, metabolic syndrome can lead to multiple complications, including diabetes. It remains unclear, which component of the metabolic syndrome (obesity, inflammation, hyperglycemia or insulin resistance) has the strongest inhibitory effect on stem cells involved in beta cell regeneration. This makes it challenging to develop effective treatment options for complications such as diabetes. In our study, experiments were performed on male C57BL/6 mice where metabolic disorders have been introduced experimentally by a combination of streptozotocin-treatment and high-fat diet. We evaluated the biological effects of Bisamide Derivative of Dicarboxylic Acid (BDDA) and its impact on pancreatic stem cells in vivo. To assess the impact of BDDA, we applied a combination of histological and biochemical methods along with a cytometric analysis of stem cell and progenitor cell markers. We show that in mice with metabolic disorders, BDDA has a positive effect on lipid and glucose metabolism. The pancreatic restoration was associated with a decrease of the inhibitory effects of inflammation and obesity factors on pancreatic stem cells. Our data show that BDDA increases the number of pancreatic stem cells. Thus, BDDA could be used as a new compound for treating complications of the metabolic syndrome such as diabetes.

Item Type:Article
Divisions:Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:88851


Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation